on October 14, 2004
Published online before print October 14, 2004, doi: 10.1161/01.ATV.0000147730.78953.60
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 16, 2004
Accepted on September 27, 2004
Molecular Evaluation of Endothelial Progenitor Cells in Patients With Ischemic Limbs. Therapeutic Effect by Stem Cell Transplantation
Koji Yamamoto *;
From the Departments of Transfusion Medicine (K.Y., S.S., J.T.), Cardiology (T.K., H.I., T.M.), Vascular Surgery (M.K., K.K.), and Hematology (N.E., T.N.), Nagoya University Hospital, Nagoya, Japan.
* To whom correspondence should be addressed. E-mail: kojiy{at}med.nagoya-u.ac.jp.
Objective--Although some patients with limb ischemia have recently undergone therapeutic angiogenesis by cell transplantation, their angiogenic potential has not been well characterized. It is also important to evaluate endothelial progenitor cell (EPC) contents in different stem cell sources to choose the best material for therapeutic angiogenesis.
Methods and Results--We quantitated the mRNA expression of EPC-specific molecules (eg, Flk-1, Flt-1, CD133, VE-cadherin, etc) in bone marrow-derived or peripheral blood-derived mononuclear cells obtained from patients with ischemic limbs, using real-time reverse-transcription polymerase chain reaction technique. The mRNA expression level of EPC markers was significantly lower in the patients than in healthy controls, which was consistent with results of flow cytometric analysis. However, the implantation of autologous bone marrow mononuclear cells increased the circulating EPCs in the peripheral blood of patients. We furthermore revealed the different expression pattern of EPC markers in possible sources for stem cell transplantation, including normal bone marrow, peripheral blood obtained from recombinant granulocyte colony-stimulating factor-treated donor, and umbilical cord blood.
Conclusions--Patients with peripheral obstructive arterial diseases may have lower angiogenic potential because of decreased expression of EPC specific molecules in their marrow and blood. Therapeutic angiogenesis by transplantation of autologous marrow mononuclear cells increased circulating EPCs in the patients and improved ischemic symptoms.
Key words: angiogenesis • stem cell • endothelial progenitor cells • transplantation • ischemia
This article has been cited by other articles:
 |
|
 |
|
  I. Al Mheid and A. A. Quyyumi Cell Therapy in Peripheral Arterial Disease Angiology, January 1, 2009; 59(6): 705 - 716. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Nevskaya, L. Ananieva, S. Bykovskaia, I. Eremin, E. Karandashov, J. Khrennikov, E. Mach, M. Zaprjagaeva, N. Guseva, and E. Nassonov Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis Rheumatology, January 1, 2009; 48(1): 61 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Werner and G. Nickenig Influence of Cardiovascular Risk Factors on Endothelial Progenitor Cells: Limitations for Therapy? Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 257 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lee, M. Aoki, T. Kondo, K. Kobayashi, K. Okumura, K. Komori, and T. Murohara Therapeutic Angiogenesis With Intramuscular Injection of Low-Dose Recombinant Granulocyte-Colony Stimulating Factor Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2535 - 2541. [Abstract] [Full Text] [PDF]
|
|